State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors

Abstract Bispecific antibodies (bsAbs) are some of the most promising biotherapeutics due to versatility provided by their structure and functional features. bsAbs simultaneously bind two antigens or epitopes on same antigen. Moreover, they capable directing immune effector cells cancer delivering various compounds (radionuclides, toxins, immunologic agents) target cells, thus offering a broad spectrum clinical applications. Current review is focused technologies used in bsAb engineering, current progress prospects these antibodies, selection heterologous expression systems for production. We also discuss platforms development therapy solid tumors.